A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients
-
Published:2024-08
Issue:2
Volume:64
Page:107235
-
ISSN:0924-8579
-
Container-title:International Journal of Antimicrobial Agents
-
language:en
-
Short-container-title:International Journal of Antimicrobial Agents
Author:
LI YingORCID, Zhu Demei, Sun Shenghua, Chang Xiaoyue, Cao Zhaolong, Yang Yanping, Fu Xiuhua, Li Xiangyang, Xu JinfuORCID, Zhu Yingqun, Hui Fuxin, Xu Xingxiang, Chen Zhang, Peng Liping, Ma Zhuang, Mo Biwen, Li Chen, Lv Yuan, Zhao Li, Zhu Guangfa, He Yong, Liu Hua, Chen Jichao, Wang Ying, Liang Yongjie, Lu Youjin, Qin Zhiqiang, Yang Hongzhong, Zhang Min, Wu Shiman, Tong Zhaohui, Ye Feng, Xiao Zuke, Wang Xuefen, Qiu Chen, Kuang Jiulong, Huang Huaping, Wang Kai, Ying Kejing, Jin Faguang, Lv Xiaoju, Huang Yijiang, Liu Deling, Wang Wei, Zhang YingyuanORCID
Reference25 articles.
1. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network;Welte;Semin Respir Crit Care Med,2009 2. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review;Peto;Trans R Soc Trop Med Hyg,2014 3. Antibiotic resistance in community-acquired pneumonia caused by Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, and Acinetobacter baumannii;Ho;Chest,2009 4. Community-acquired methicillin-resistant Staphylococcus aureus pneumonia in a children's hospital. Our ten-year experience;Ensinck;Arch Argent Pediatr,2021 5. CHINET surveillance of bacterial resistance across tertiary hospitals in 2019;Hu;Chin J Infect Chemother,2020
|
|